
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical cream containing colchicine, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing colchicine are listed in tablet, capsule and solution forms. No finished colchicine product of any kind is listed in cream form.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Colchicine is an anti-inflammatory alkaloid taken by mouth that a pharmacy may compound when a prescriber orders it.
Colchicine is an anti-inflammatory alkaloid. It blocks microtubule assembly inside white blood cells called neutrophils, keeping them from activating and moving to inflamed tissue, and interferes with a signaling complex that activates interleukin-1 beta. Manufactured products include colchicine tablets (approved under an NDA, including authorized generics), labeled for prevention and treatment of gout flares in adults and for familial Mediterranean fever in adults and children 4 years and older; colchicine capsules (an NDA authorized generic), labeled for prevention of gout flares in adults; and Lodoco tablets, labeled to reduce the risk of heart attack, stroke, coronary revascularization and cardiovascular death in adults with atherosclerotic disease or multiple cardiovascular risk factors. A prescriber might order colchicine compounded in a form or strength that is not manufactured, or without a particular excipient. Compounded preparations are not FDA-approved and require a prescription.
Colchicine labels carry no boxed warning, but fatal overdoses have occurred in adults and children, so keep it out of reach of children. It can lower blood cell counts, and it can cause muscle damage, especially in older adults and people with kidney problems. Some medicines, including clarithromycin, erythromycin, verapamil, cyclosporine, and grapefruit juice, can raise colchicine levels to dangerous amounts; people with kidney or liver problems must not combine it with drugs that block both P-gp and CYP3A4, and people with both kidney and liver problems should not take it. Diarrhea, nausea, vomiting and stomach pain can be early signs of toxicity. Contact your prescriber right away for muscle pain or weakness, tingling, unusual bruising or bleeding, or signs of infection. Colchicine passes into breast milk; LactMed reports no infant harm in case series. Talk to your prescriber or pharmacist about side effects.
Colchicine disrupts beta-tubulin polymerization into microtubules, preventing neutrophil activation, degranulation and migration, and interferes with the inflammasome that mediates IL-1 beta activation (Hikma label). Per that label, absolute oral bioavailability is about 45% and food does not alter absorption; volume of distribution is about 5 to 8 L/kg and protein binding about 39%; it is a substrate of CYP3A4 and P-gp, 40 to 65% of an absorbed dose is excreted unchanged in urine, elimination half-life is about 31 hours, and the label states that hemodialysis does not adequately remove colchicine. Labeled indications: gout flare prophylaxis and treatment and FMF (tablets, NDA022352 authorized generic), gout flare prophylaxis (capsules, NDA204820 authorized generic), and cardiovascular risk reduction (Lodoco). StatPearls lists acute and recurrent pericarditis, primary biliary cirrhosis, pseudogout, dermatitis herpetiformis and other conditions as off-label uses; these are not FDA-approved indications. StatPearls notes a narrow therapeutic index with no routine serum assay and advises monitoring complete blood count and renal and hepatic function. Avoid or reduce dosing with CYP3A4 or P-gp inhibitors per the label. Dosing is per prescriber.
Wash your hands. Apply the amount on your label to clean, dry skin and rub it in gently. For a metered pump, each press delivers a set amount; your label states how many presses. For transdermal creams, apply to the area your label names and let it dry before dressing. Wash your hands afterward and avoid skin-to-skin contact with others at the application site until it has absorbed. Do not apply to broken skin unless told to.
Creams are aqueous. Under USP <795>, a preserved cream usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Follow the storage line on your label, keep from freezing, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)